Engineered myeloid cells may prevent metastasisMay 8, 2021
Sabina Kaczanowska et al developed genetically engineered myeloid cells (GEMys) that could help alter the metastatic environment of a tumour and prevent it from spreading. The team identified an immune-suppressing programme in a pre-metastatic tumour environment that predominantly involved myeloid cells. The myeloid cells in the premetastatic niche allowed cancer cells to thrive when they spread there. The study, therefore, targeted and reversed immune suppression by utilising the GEMys to deliver interleukin 12 (IL-12) to modulate the metastatic microenvironment. The findings showed that IL12-GEMy treatment in rhabdomyosarcoma mice models reversed immune suppression by activating antigen presentation and T cell activation. The treatment resulted in reduced metastatic and primary tumour burden and improved survival of the tumour-bearing mice by rebalancing the dysregulated metastatic microenvironment in cancer.
Source: Cell |24 March 2021| https://doi.org/10.1016/j.cell.2021.02.048